However, inhibition of both signalling pathways, JAK/STAT and MAPK/ERK1,2, with ruxolitinib and trametinib, respectively, caused a significant reduction in the generation of mROS in HSVSMCs from both T2DM and non-diabetic patients. Here, SOAT1 is linked to type 2 diabetes mellitus.